Cano Health Analyst Ratings
Cano Health Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | -47.37% | Citigroup | $4 → $0.8 | Downgrades | Buy → Neutral |
| 05/16/2023 | -34.21% | Piper Sandler | $0.5 → $1 | Maintains | Underweight |
| 05/12/2023 | 64.47% | Credit Suisse | → $2.5 | Reiterates | Neutral → Neutral |
| 01/06/2023 | -17.76% | UBS | $12 → $1.25 | Downgrades | Buy → Neutral |
| 01/05/2023 | — | Wolfe Research | Downgrades | Outperform → Peer Perform | |
| 12/13/2022 | -1.32% | B of A Securities | → $1.5 | Reinstates | → Underperform |
| 11/16/2022 | 228.95% | Citigroup | $7 → $5 | Maintains | Buy |
| 11/10/2022 | 97.37% | Cowen & Co. | $10 → $3 | Downgrades | Outperform → Market Perform |
| 11/10/2022 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 10/27/2022 | 228.95% | Credit Suisse | $10 → $5 | Downgrades | Outperform → Neutral |
| 09/07/2022 | 360.53% | Truist Securities | → $7 | Initiates Coverage On | → Hold |
| 08/10/2022 | 163.16% | Piper Sandler | $4 → $4 | Maintains | Underweight |
| 06/24/2022 | 426.32% | Raymond James | → $8 | Initiates Coverage On | → Outperform |
| 06/15/2022 | 294.74% | B of A Securities | $8 → $6 | Downgrades | Buy → Neutral |
| 05/11/2022 | 557.89% | Credit Suisse | $13 → $10 | Maintains | Outperform |
| 05/11/2022 | 163.16% | Piper Sandler | $5 → $4 | Maintains | Underweight |
| 05/10/2022 | 426.32% | Citigroup | $10 → $8 | Maintains | Buy |
| 05/03/2022 | 426.32% | B of A Securities | → $8 | Initiates Coverage On | → Buy |
| 04/20/2022 | 886.84% | UBS | → $15 | Initiates Coverage On | → Buy |
| 04/06/2022 | 228.95% | Piper Sandler | $8.5 → $5 | Downgrades | Neutral → Underweight |
| 03/16/2022 | 755.26% | Credit Suisse | $15 → $13 | Maintains | Outperform |
| 11/10/2021 | 755.26% | Piper Sandler | $11 → $13 | Maintains | Neutral |
| 10/20/2021 | 1018.42% | Jefferies | → $17 | Initiates Coverage On | → Buy |
| 10/19/2021 | 623.68% | Piper Sandler | → $11 | Initiates Coverage On | → Neutral |
| 10/01/2021 | 1150% | Wolfe Research | → $19 | Initiates Coverage On | → Outperform |
| 09/21/2021 | 1215.79% | Citigroup | → $20 | Initiates Coverage On | → Buy |
| 09/10/2021 | 1084.21% | Cowen & Co. | → $18 | Initiates Coverage On | → Outperform |
| 08/02/2021 | 1084.21% | Credit Suisse | → $18 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/11/2023 | -47.37% | 花旗集团 | 4 美元 → 0.8 美元 | 降级 | 买入 → 中性 |
| 05/16/2023 | -34.21% | 派珀·桑德勒 | 0.5 美元 → 1 美元 | 维护 | 体重不足 |
| 05/12/2023 | 64.47% | 瑞士信贷 | → 2.5 美元 | 重申 | 中性 → 中性 |
| 01/06/2023 | -17.76% | 瑞银（UBS） | 12 美元 → 1.25 美元 | 降级 | 买入 → 中性 |
| 01/05/2023 | — | 沃尔夫研究 | 降级 | 跑赢大盘 → 同行表现 | |
| 12/13/2022 | -1.32% | B of A 类证券 | → 1.5 美元 | 恢复 | → 表现不佳 |
| 11/16/2022 | 228.95% | 花旗集团 | 7 美元 → 5 美元 | 维护 | 购买 |
| 2022 年 10 月 11 日 | 97.37% | Cowen & Co. | 10 美元 → 3 美元 | 降级 | 跑赢大盘 → 市场表现 |
| 2022 年 10 月 11 日 | — | 雷蒙德·詹姆 | 降级 | 跑赢大盘 → 市场表现 | |
| 10/27/2022 | 228.95% | 瑞士信贷 | 10 美元 → 5 美元 | 降级 | 跑赢大盘 → 中性 |
| 09/07/2022 | 360.53% | 信托证券 | → 7 美元 | 启动覆盖开启 | → 按住 |
| 08/10/2022 | 163.16% | 派珀·桑德勒 | 4 美元 → 4 美元 | 维护 | 体重不足 |
| 2022 年 6 月 24 日 | 426.32% | 雷蒙德·詹姆 | → 8 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 06/15/2022 | 294.74% | B of A 类证券 | 8 美元 → 6 美元 | 降级 | 买入 → 中性 |
| 05/11/2022 | 557.89% | 瑞士信贷 | 13 美元 → 10 美元 | 维护 | 跑赢大盘 |
| 05/11/2022 | 163.16% | 派珀·桑德勒 | 5 美元 → 4 美元 | 维护 | 体重不足 |
| 05/10/2022 | 426.32% | 花旗集团 | 10 美元 → 8 美元 | 维护 | 购买 |
| 05/03/2022 | 426.32% | B of A 类证券 | → 8 美元 | 启动覆盖开启 | → 购买 |
| 04/20/2022 | 886.84% | 瑞银（UBS） | → 15 美元 | 启动覆盖开启 | → 购买 |
| 04/06/2022 | 228.95% | 派珀·桑德勒 | 8.5 美元 → 5 美元 | 降级 | 中性 → 体重不足 |
| 2022 年 3 月 16 日 | 755.26% | 瑞士信贷 | 15 美元 → 13 美元 | 维护 | 跑赢大盘 |
| 11/10/2021 | 755.26% | 派珀·桑德勒 | 11 美元 → 13 美元 | 维护 | 中立 |
| 2021 年 10 月 20 日 | 1018.42% | 杰富瑞 | → 17 美元 | 启动覆盖开启 | → 购买 |
| 10/19/2021 | 623.68% | 派珀·桑德勒 | → 11 美元 | 启动覆盖开启 | → 中立 |
| 2021 年 1 月 10 日 | 1150% | 沃尔夫研究 | → 19 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 09/21/2021 | 1215.79% | 花旗集团 | → 20 美元 | 启动覆盖开启 | → 购买 |
| 2021 年 10 月 9 日 | 1084.21% | Cowen & Co. | → 18 美元 | 启动覆盖开启 | → 跑赢大盘 |
| 2021 年 2 月 8 日 | 1084.21% | 瑞士信贷 | → 18 美元 | 启动覆盖开启 | → 跑赢大盘 |
What is the target price for Cano Health (CANO)?
Cano Health（CANO）的目标价格是多少？
The latest price target for Cano Health (NYSE: CANO) was reported by Citigroup on August 11, 2023. The analyst firm set a price target for $0.80 expecting CANO to fall to within 12 months (a possible -47.37% downside). 11 analyst firms have reported ratings in the last year.
花旗集团于2023年8月11日公布了Cano Health（纽约证券交易所代码：CANO）的最新目标股价。这家分析公司将目标股价定为0.80美元，预计CANO将在12个月内跌至-47.37％（可能下跌-47.37％）。去年有11家分析公司公布了评级。
What is the most recent analyst rating for Cano Health (CANO)?
分析师对Cano Health（CANO）的最新评级是多少？
The latest analyst rating for Cano Health (NYSE: CANO) was provided by Citigroup, and Cano Health downgraded their neutral rating.
Cano Health（纽约证券交易所代码：CANO）的最新分析师评级由花旗集团提供，Cano Health下调了中性评级。
When is the next analyst rating going to be posted or updated for Cano Health (CANO)?
Cano Health（CANO）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cano Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cano Health was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Cano Health的高管和客户交谈以及听取财报电话会议）后得出股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Cano Health 的最后一次评级是在2023年8月11日提交的，因此你应该预计下一个评级将在2024年8月11日左右公布。
Is the Analyst Rating Cano Health (CANO) correct?
分析师对 Cano Health (CANO) 的评级正确吗？
While ratings are subjective and will change, the latest Cano Health (CANO) rating was a downgraded with a price target of $4.00 to $0.80. The current price Cano Health (CANO) is trading at is $1.52, which is out of the analyst's predicted range.
虽然评级是主观的，会发生变化，但最新的Cano Health（CANO）评级被下调，目标股价为4.00美元至0.80美元。Cano Health（CANO）目前的交易价格为1.52美元，超出了分析师的预测区间。